These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11401142)

  • 41. The antithrombotic efficacy of lotrafiban (SB 214857) in canine models of acute coronary thrombosis.
    Toomey JR; Samanen J; Valocik RE; Koster PF; Barone FC; Willette RN
    Curr Drug Targets Cardiovasc Haematol Disord; 2002 Jun; 2(1):13-25. PubMed ID: 12769654
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Endogenous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis.
    Yao SK; Akhtar S; Scott-Burden T; Ober JC; Golino P; Buja LM; Casscells W; Willerson JT
    Circulation; 1995 Aug; 92(4):1005-10. PubMed ID: 7641335
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.
    Weimann J; Ullrich R; Hromi J; Fujino Y; Clark MW; Bloch KD; Zapol WM
    Anesthesiology; 2000 Jun; 92(6):1702-12. PubMed ID: 10839922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury.
    Rubenstein MH; Finn AV; Leinbach RC; Hollenbach S; Aretz HT; Virmani R; Gold HK
    J Am Coll Cardiol; 2004 Jan; 43(2):287-94. PubMed ID: 14736451
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U; Dörge L; Fischer S
    Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of trimetazidine on in vivo coronary arterial platelet thrombosis.
    Belcher PR; Drake-Holland AJ; Hynd JW; Noble MI
    Cardiovasc Drugs Ther; 1993 Feb; 7(1):149-57. PubMed ID: 8485070
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Localized administration of sodium nitroprusside enhances its protection against platelet aggregation in stenosed and injured coronary arteries.
    Willerson JT; Igo SR; Yao SK; Ober JC; Macris MP; Ferguson JJ
    Tex Heart Inst J; 1996; 23(1):1-8. PubMed ID: 8680268
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries.
    Demrow HS; Slane PR; Folts JD
    Circulation; 1995 Feb; 91(4):1182-8. PubMed ID: 7850957
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
    Nicolini FA; Mehta JL; Nichols WW; Saldeen TG; Grant M
    Circulation; 1990 Mar; 81(3):1115-22. PubMed ID: 1689620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
    Yasuda T; Gold HK; Fallon JT; Leinbach RC; Guerrero JL; Scudder LE; Kanke M; Shealy D; Ross MJ; Collen D; Coller BS
    J Clin Invest; 1988 Apr; 81(4):1284-91. PubMed ID: 2832448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early intravenous administration of metoprolol enhances myocardial salvage by thrombolysis with recombinant tissue-type plasminogen activator after thrombotic coronary artery occlusion in the dog by improvement of the collateral blood flow to the area at risk.
    Zmudka K; Aubert A; Dubiel J; Vanhaecke J; Flameng W; Kaczmarek J; De Geest H
    J Am Coll Cardiol; 1994 May; 23(6):1499-504. PubMed ID: 8176113
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator.
    Prewitt RM; Gu S; Garber PJ; Ducas J
    J Am Coll Cardiol; 1992 Dec; 20(7):1626-33. PubMed ID: 1452937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced thrombolysis, reduced coronary reocclusion and limitation of infarct size with liposomal prostaglandin E1 in a canine thrombolysis model.
    Feld S; Li G; Amirian J; Felli P; Vaughn WK; Accad M; Tolleson TR; Swenson C; Ostro M; Smalling RW
    J Am Coll Cardiol; 1994 Nov; 24(5):1382-90. PubMed ID: 7930264
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intraplatelet tetrahydrobiopterin plays an important role in regulating canine coronary arterial thrombosis by modulating intraplatelet nitric oxide and superoxide generation.
    Kanaya S; Ikeda H; Haramaki N; Murohara T; Imaizumi T
    Circulation; 2001 Nov; 104(20):2478-84. PubMed ID: 11705828
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA; Mellott MJ; Garsky VM; Shebuski RJ
    Pharmacology; 1991; 42(6):340-8. PubMed ID: 1946598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
    Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Direct effects of selective type 5 phosphodiesterase inhibitors alone or with other vasodilators on the erectile response in cats.
    Doherty PC; Bivalacqua TJ; Champion HC; Kadowitz PJ; Greenwood-Van Meerveld B; Berzetei-Gurske I; Hellstrom WJ
    J Urol; 2001 Mar; 165(3):1004-9. PubMed ID: 11176530
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P; Ashton JH; Glas-Greenwalt P; McNatt J; Buja LM; Willerson JT
    Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term inhaled nitric oxide plus dipyridamole for pulmonary arterial hypertension.
    Pérez-Peñate G; Cabrera Navarro P; Ponce González M; Górriz Gómez E; Pulido Duque J; García Quintana A; Juliá Serdá G
    Respiration; 2005; 72(4):419-22. PubMed ID: 16088287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.